4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
C4 Therapeutics, Inc. (CCCC) operates in the Biotechnology industry and is headquartered in Watertown, United States with about 104 employees. Its market capitalization is roughly $420 million. In the fiscal year ended 2025-12-31, CCCC reported $36M in revenue and ($105M) in net income.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins.
Interactive charts & full statements → Open the CCCC valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $36M | $36M | $21M | $31M | — |
| Operating Income (EBIT) | ($104M) | ($117M) | ($139M) | ($130M) | — |
| Net Income | ($105M) | ($105M) | ($132M) | ($128M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $6M | $11M | $11M | $6M | $7M | — |
| Operating Income (EBIT) | ($28M) | ($23M) | ($24M) | ($28M) | ($29M) | — |
| Net Income | ($25M) | ($20M) | ($32M) | ($26M) | ($26M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $359M | $350M | $376M | $431M | — |
| Total Liabilities | $102M | $134M | $130M | $142M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CCCC viewer.
About TickerBase · Data methodology & sources